Loading
Life sciences · Journal article
Frontiers in Molecular Biosciences · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Colorectal cancer is a leading cause of cancer-related mortality worldwide, underscoring the need for effective therapies with lower toxicity. Probiotic-derived metabolites (postbiotics) have emerged as promising anticancer components with immunomodulatory and antiproliferative effects. Methods Cell-Free Supernatant (CFS) from Lactobacillus rhamnosus GG, produced under microaerophilic conditions and characterized by GC-MS, was tested against HT-29 colorectal adenocarcinoma cells. Cytotoxicity was evaluated by MTT assay, apoptosis following Annexin V-FITC/PI flow cytometry, and cell cycle distribution. Results Growth under microaerophilic conditions yielded a sterile CFS that was subsequently profiled by GC-MS. Cytotoxicity was assessed by MTT assay, while apoptosis and cell-cycle distribution were evaluated by flow cytometry. GC-MS showed more than 65 chromatographic peaks, and 28 major compounds were tentatively identified by NIST-library matching; diketopiperazines accounted for approximately 45% of the total identified peak area. The study-strain CFS reduced HT-29 cell viability in a concentration-dependent manner, with an estimated IC50 of 14.2 micrograms/mL expressed as total lyophilized solids. Annexin V-FITC/PI flow cytometry showed 47.6 ± 2.9% early apoptotic, 2.3 ± 0.8% late apoptotic, 2.3 ± 0.6% necrotic, and 47.8 ± 3.2% viable cells after treatment. Treated cells were distributed as 47.3% G1, 38.9% S, 3.22% G2/M, and 2.60% sub-G1; because reliable quantitative control data were unavailable, phase-specific arrest could not be established. Conclusion The study-strain CFS showed concentration-dependent in vitro cytotoxic and pro-apoptotic activity against HT-29 cells. The activity may be associated with the partial metabolite profile identified by GC-MS, but specific active compounds and molecular pathways were not established. The cell-cycle findings are descriptive because reliable quantitative control data were unavailable. Further studies using processed-medium controls, non-transformed colonic cells, additional cancer cell lines, orthogonal viability assays, mechanistic markers, and activity-guided fractionation are required.